Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640

January 4, 2024

https://www.globenewswire.com/news-release/2024/01/04/2803835/0/en/Rhythm-Pharmaceuticals-and-LG-Chem-Life-Sciences-Enter-Agreement-for-Rhythm-to-Acquire-Global-Rights-to-Oral-MC4R-Agonist-LB54640.html

— LB54640 has shown targeted effect on MC4 receptor without hyperpigmentation —

— Rhythm to advance LB54640 in two Phase 2 clinical trials —

Read more at globenewswire.com

Related news for (RYTM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.